Haisco drug for muscular dystrophy advances to clinical trials

Haisco Pharmaceutical Group's subsidiary, Shanghai Haisco Shengno Pharmaceutical Technology, recently announced that the National Medical Products Administration has accepted its investigational new drug application for HSK36357 capsules for a new indication. The drug, classified as a Class 1 chemical drug, is proposed for treating muscular dystrophy, including Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy.

This acceptance signifies the drug's progression to registered clinical trials for this new indication. Non-clinical studies have shown that HSK36357 not only has significant analgesic effects but also improves muscle contraction and recovery from fatigue in DMD model mice.

This development follows the prior approval of HSK36357 for clinical trials for peripheral neuropathic pain. Haisco Pharmaceutical cautions investors about the inherent risks associated with innovative drug development, citing long research cycles, multiple stages, and high uncertainties. The company pledges to provide timely disclosure on future developments of this project.